[admin]

Custom Pharmaceutical Intermediate R&D Services: What Buyers Need to Know

Pharmaceutical companies, CRO/CDMO institutions, and generic drug developers evaluating custom pharmaceutical intermediate R&D services face a recurring set of challenges: extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality that disrupts production schedules, fragmented sourcing across multiple suppliers that raises procurement costs, and difficulty matching process parameters for niche intermediate categories. Upstream intermediate introductions often lag behind new drug iteration cycles, leaving development teams without the building blocks they need when clinical timelines accelerate.

Shandong Tianming Pharmaceutical Group, operating under the brand name Tianming Pharmaceutical, addresses these pain points through an integrated R&D-production model that supplies API, intermediates, and CMO/CDMO custom development and production solutions to the global pharmaceutical industry. The company is recognized as a National High-Tech Enterprise and has built its business around the specific procurement difficulties that generic and innovator companies encounter when sourcing specialty intermediates.

Why Full-Chain Intermediate Coverage Matters

One of the most cited inefficiencies in intermediate sourcing is the need to coordinate multiple suppliers to cover different stages of a synthesis pathway. Tianming Pharmaceutical’s differentiated advantage lies in its full-chain product matrix, which covers N-1 to N-5 intermediates for flagship molecules including Sacubitril Valsartan Sodium, Orforglipron, and Finerenone.

For Orforglipron, an oral non-peptide small molecule GLP-1 receptor agonist that has entered Phase III clinical trials, the company offers a complete product ladder from starting materials through advanced intermediates to API, including 12 key intermediate CAS numbers spanning the synthesis pathway, plus multiple key impurity reference standards for quality analysis and method development. This structure allows innovator companies, CMO/CDMO partners, and advanced generic companies preparing for future patent challenges to source from a single supplier rather than managing several vendors, each with different specifications and lead times.

A similar full-chain approach applies to the Sacubitril Valsartan Sodium series (LCZ696, brand name Entresto), the inaugural angiotensin receptor neprilysin inhibitor (ARNI) for heart failure treatment. With the US core patent having expired in July 2023 and the China compound patent expiring in 2026, generic pharmaceutical companies are working within a defined window to secure qualified, cost-competitive Sacubitril Calcium suppliers for R&D, regulatory filing, and pre-launch inventory. Tianming Pharmaceutical supplies the full ladder from starting materials such as ethoxycarbonylmethylene triphenylphosphorane (CAS 5717373) through advanced chiral intermediates to the finished Sacubitril Valsartan Sodium co-crystal API (CAS 936623904), including Sacubitril Calcium (CAS 1369773396), which also supports independent intellectual property NCE development such as Sacubitril Alisartan Calcium.

Quality Control Standards for Registration-Grade Intermediates

Custom pharmaceutical intermediate R&D services are only useful to customers if the resulting materials meet the specifications required for regulatory filings. Tianming Pharmaceutical applies quality specifications that the company states exceed industry norms: Sacubitril Calcium is controlled to an individual impurity below 0.1% and chiral purity above 99.5%, while Orforglipron intermediates are held to an individual impurity below 0.1%, total impurities below 0.5%, enantiomer below 0.1%, and content above 98.0%. Quality control extends beyond single-parameter testing to include strict monitoring of the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form.

This level of documentation is paired with full technical files — COA, MOA methodology, impurity profile studies, and stability data — that support DMF and CEP global regulatory filings, a requirement for any generic or CDMO customer moving a product toward commercial launch.

R&D Infrastructure Behind Custom Development Work

Custom intermediate development depends on laboratory capacity, analytical instrumentation, and process chemistry expertise. Tianming Pharmaceutical operates two R&D centers — in Jinan and Nanjing — with a combined laboratory area exceeding 6,000 square meters and an R&D team of more than 100 personnel. The centers are equipped with over RMB 40 million in professional R&D and testing equipment, including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments, supported by an IPD integrated product development management system that spans laboratory small-scale work, process pilot studies, and industrial scale-up.

 

The company allocates above 10% of annual revenue to R&D innovation, compared with an industry average around 5%, with an additional 1% of revenue directed toward management system iteration. This investment underpins independent process development work, such as the route optimization completed for Orforglipron full-chain intermediates and the Sacubitril series, where multiple rounds of process validation were carried out to ensure the routes are suited for industrial scale-up while maintaining batch-to-batch consistency.

 

From Laboratory Sample to Commercial Volume

A defining feature of Tianming Pharmaceutical’s service model is coverage across the entire development lifecycle: pre-sales consultation, sample supply at gram-level, hundred-gram, and pilot scale, custom R&D, process optimization, scale-up, and commercial supply, plus logistics coordination, customs clearance, and trade insurance support for international orders. Products move from gram-level to ton-level, with three coordinated production bases operating more than 160 reactor vessels and annual production capacity in the hundreds of tons.

 

For customers with time-sensitive projects, in-stock orders are delivered within 7–15 working days, covering order confirmation, quality review, packaging, and shipping, while made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability. Expedited production scheduling is available for urgent projects. Support is structured around a 1-on-1 account manager plus technical engineer model: routine technical issues receive reference solutions within 2 hours, and complex technical issues are addressed with a written report within 24 hours, with periodic follow-up visits and on-site technical support available for bulk and framework customers.

Operating Scale and Market Position

Founded as a group entity in 2020, with its predecessor Shandong Sihuan Pharmaceutical Co., Ltd. established in 2010, Tianming Pharmaceutical Group now coordinates two R&D centers, three domestic production bases in Dezhou, Jining, and Hechi, and two overseas business entities in India and Bangladesh. The organization employs more than 400 people and works with more than 2,000 cooperative customers across East China, North China, and South China pharmaceutical industry clusters domestically, and more than 30 countries and regions across South Asia, Southeast Asia, the Middle East, Central and South America, and Africa internationally.

Within its market, pharmaceutical companies account for 56.7% of overall demand for this type of supply relationship, and CRO/CDMO institutions account for 28.6%, with quality stability and process compatibility ranking above procurement price as selection criteria — a pattern consistent with the registration-grade documentation and full-chain coverage that custom pharmaceutical intermediate R&D services are expected to provide. Supported by a GMP-compliant quality assurance system, ISO9001 certification, and CRM, ERP, and BPM digital management systems for order and production coordination, Tianming Pharmaceutical Group presents itself as a structured option for organizations seeking coordinated, well-documented intermediate development and supply from early-stage R&D through commercial-scale delivery.

Home

Tianming Pharmaceutical Group

[Author]

Posts